The RalGEF/Ral Pathway. Evaluating an Intervention Opportunity for Ras Cancers.

Jonathan M. Cooper, Brian O. Bodemann, Michael A. White

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Recognition that Ral guanine nucleotide exchange factors (RalGEFs) are direct Ras effectors and that Ral G-protein activation is a direct consequence of Ras activation has spurred focused efforts to establish the contribution of RalGEF/Ral signaling to oncogenic transformation. Here, we provide a broad-strokes overview of the mechanistic organization of the RalGEF/Ral signaling network, evaluate the evidence for participation of this network in tumorigenic regulatory milieus, consider targeting strategies, and discuss the challenges to and opportunities for clinical development of these targeting strategies.

Original languageEnglish (US)
Pages (from-to)137-156
Number of pages20
JournalEnzymes
Volume34
DOIs
StatePublished - 2013

Fingerprint

ral Guanine Nucleotide Exchange Factor
ral GTP-Binding Proteins
Chemical activation
Neoplasms
GTP-Binding Proteins

Keywords

  • Cancer
  • Exo84
  • Exocyst
  • K-Ras
  • MTORC1
  • RalA
  • RalB
  • RALBP1
  • Sec5
  • TBK1
  • ULK1

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Biophysics
  • Molecular Biology

Cite this

The RalGEF/Ral Pathway. Evaluating an Intervention Opportunity for Ras Cancers. / Cooper, Jonathan M.; Bodemann, Brian O.; White, Michael A.

In: Enzymes, Vol. 34, 2013, p. 137-156.

Research output: Contribution to journalArticle

Cooper, Jonathan M. ; Bodemann, Brian O. ; White, Michael A. / The RalGEF/Ral Pathway. Evaluating an Intervention Opportunity for Ras Cancers. In: Enzymes. 2013 ; Vol. 34. pp. 137-156.
@article{c5ff9370adac4dfc844294ae3733fc73,
title = "The RalGEF/Ral Pathway. Evaluating an Intervention Opportunity for Ras Cancers.",
abstract = "Recognition that Ral guanine nucleotide exchange factors (RalGEFs) are direct Ras effectors and that Ral G-protein activation is a direct consequence of Ras activation has spurred focused efforts to establish the contribution of RalGEF/Ral signaling to oncogenic transformation. Here, we provide a broad-strokes overview of the mechanistic organization of the RalGEF/Ral signaling network, evaluate the evidence for participation of this network in tumorigenic regulatory milieus, consider targeting strategies, and discuss the challenges to and opportunities for clinical development of these targeting strategies.",
keywords = "Cancer, Exo84, Exocyst, K-Ras, MTORC1, RalA, RalB, RALBP1, Sec5, TBK1, ULK1",
author = "Cooper, {Jonathan M.} and Bodemann, {Brian O.} and White, {Michael A.}",
year = "2013",
doi = "10.1016/B978-0-12-420146-0.00006-8",
language = "English (US)",
volume = "34",
pages = "137--156",
journal = "Enzymes",
issn = "0423-2607",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The RalGEF/Ral Pathway. Evaluating an Intervention Opportunity for Ras Cancers.

AU - Cooper, Jonathan M.

AU - Bodemann, Brian O.

AU - White, Michael A.

PY - 2013

Y1 - 2013

N2 - Recognition that Ral guanine nucleotide exchange factors (RalGEFs) are direct Ras effectors and that Ral G-protein activation is a direct consequence of Ras activation has spurred focused efforts to establish the contribution of RalGEF/Ral signaling to oncogenic transformation. Here, we provide a broad-strokes overview of the mechanistic organization of the RalGEF/Ral signaling network, evaluate the evidence for participation of this network in tumorigenic regulatory milieus, consider targeting strategies, and discuss the challenges to and opportunities for clinical development of these targeting strategies.

AB - Recognition that Ral guanine nucleotide exchange factors (RalGEFs) are direct Ras effectors and that Ral G-protein activation is a direct consequence of Ras activation has spurred focused efforts to establish the contribution of RalGEF/Ral signaling to oncogenic transformation. Here, we provide a broad-strokes overview of the mechanistic organization of the RalGEF/Ral signaling network, evaluate the evidence for participation of this network in tumorigenic regulatory milieus, consider targeting strategies, and discuss the challenges to and opportunities for clinical development of these targeting strategies.

KW - Cancer

KW - Exo84

KW - Exocyst

KW - K-Ras

KW - MTORC1

KW - RalA

KW - RalB

KW - RALBP1

KW - Sec5

KW - TBK1

KW - ULK1

UR - http://www.scopus.com/inward/record.url?scp=84887219261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887219261&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-420146-0.00006-8

DO - 10.1016/B978-0-12-420146-0.00006-8

M3 - Article

C2 - 25034103

AN - SCOPUS:84887219261

VL - 34

SP - 137

EP - 156

JO - Enzymes

JF - Enzymes

SN - 0423-2607

ER -